Orexigen Therapeutics, Inc. at Bank of America Merrill Lynch Global Healthcare Conference (Replay)
09/18/14 at 4:10 p.m. UKT
Orexigen Therapeutics Conference Call (Replay)
09/11/14 at 8:30 a.m. ET
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32 (naltrexone sustained release (SR) / bupropion SR). Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company hasMore >>
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.